Formycon | Sustainability Performance
This biopharmaceutical company specializes in the development of biosimilars and therapeutics. They focus on delivering high-quality treatments to improve patient care.
1999
Germany
201 - 500 employees
Biotechnology
$25M - 100M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#2290
Overall#103
in Germany#34
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Environmental
Digital emissionsGovernance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Digital Emissions
CO2e per visit (g)
Industry benchmark
B/M 0.26 g
Green HostingYes
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$49.7MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
27.3%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-16.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.1
▼ 1.9%
0.1
▲ 11.4%
0.0
▼ 18.0%
0.2
2029Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
30%
Independent Directors
3 out of 10 incl. management
Overall score
0
Environment
0
Social
0
Governance
0
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
